

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**BOX PATENT APPLICATION** COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Transmitted herewith for filing is the patent application of:

Inventor(s): Lawrence A. Wolfraim and John Letterio

FUNCTIONALIZED TGF-BETA FUSION PROTEINS For:

Enclosed are:

$\boxtimes$	70 pages of specification, 9 pages of claims, an abstract and a Combined			
	Declaration and Power of Attorney.			
$\bowtie$	7 sheets of drawings.			
$\overline{\boxtimes}$	58 pages of sequence listing.			
	Computer Readable Form.			

Statement in Compliance. Information Disclosure Statement.

Form PTO-1449 and copies of 42 documents listed thereon.

Request for Non-publication and Certification under 35 U.S.C. § 122(b)(2)(B)(i).

FILING FEE						
	Claims	Number		Number		Basic Fee
For	Filed	Free		Extra	Rate	\$740.00
Total Claims	56	20	=	36	\$18.00	\$648.00
Independent Claims	3	3	=	0	\$84.00	\$0.00
Multiple Dependent Claim Fee \$280.00				\$0.00		
TOTAL FILING FEE					\$1,388.00	

	Applicants claim the benefit of the earlier filing date of U.S. Provisional Application No. 60/242,292 filed on October 20, 2000. The entire disclosure of provisional application No. 60/242,292 is considered to be part of the disclosure of the accompanying application and is incorporated herein by reference.
$\boxtimes$	A check in the amount of \$1,388.00 to cover ⊠ filing fee and □ assignment recordal

$\boxtimes$	The Director is hereby authorized to charge any additional fees that may be required
	in connection with the filing of this application and recording any assignment filed
	herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is
	enclosed

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Tanya M. Harding, Ph.D. Registration No. 42,630

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc: Docketing

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wolfraim and Letterio

For:

FUNCTIONALIZED TGF-BETA FUSION PROTEINS

Examiner: Not yet assigned

Date: October 19, 2001

Art Unit: Not yet assigned

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

# REQUEST FOR NON-PUBLICATION AND CERTIFICATION UNDER

#### 35 U.S.C. § 122(b)(2)(B)(i)

Applicant may rescind this nonpublication request at any time. See "Request to Rescind Previous Nonpublication Request". If applicant rescinds a request that an application not be published under 35 U.S.C. § 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. § 122 (b)(2)(B)(iii)).

This request is signed in compliance with 37 CFR § 1.33(b) and is submitted with the application upon filing. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. § 122(b).

Dated: October 19, 2001

Respectfully submitted,

KLARQUIST SPARKMAN, DI

Tanya M. Harding, Ph.D. Registration No. 42,630

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391 Facsimile: (503) 228-9446

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wolfraim and Letterio

Art Unit: Not yet assigned \*

Application No. Not yet assigned

Filed: Herewith

For: FUNCTIONALIZED TGF-BETA FUSION

**PROTEINS** 

Examiner: Not yet assigned

Date: October 19, 2001

## STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)

COMMISSIONER FOR PATENTS Washington, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of the "Sequence Listing."

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Tanya M. Harding, Ph.D. Registration No. 42,630

One World Trade Center, Suite 1600 121 S.W. Salmon Street

Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446